AKT/mTOR signaling modulates resistance to endocrine therapy and CDK4/6 inhibition in metastatic breast cancers von Abu-Khalaf, Maysa M., Alex Hodge, K., Hatzis, Christos, Baldelli, Elisa, El Gazzah, Emna, Valdes, Frances, Sikov, William M., Mita, Monica M., Denduluri, Neelima, Murphy, Rita, Zelterman, Daniel, Liotta, Lance, Dunetz, Bryant, Dunetz, Rick, Petricoin, Emanuel F., Pierobon, Mariaelena

Volltext

518 First-in-human results with the novel tumor-targeting antibody ATRC-101: phase 1b study in patients with solid tumors von Powderly, John, Jones, Jeremy, Bekaii-Saab, Tanios, Xing, Yan, John Weroha, S, Ulahannan, Susanna, Doroshow, Deborah, Valdes-Albini, Frances, Millward, Carl, Walter, Kimberly, Wrong, Andrew, Castillo, Paul Del, Wang, Lixia, Nguyen, Ngan, Whidden, Mark, Benjamin, Jonathan, Isakoff, Steven

Volltext

Tandem High-dose Chemotherapy Followed by Autologous Transplantation in Patients with Locally Advanced or Metastatic Sarcoma von LASHKARI, Ashkan, CHOW, Warren A, SOMLO, George, VALDES, Frances, LEONG, Lucille, PHAN, V. U, TWARDOWSKI, Przemyslaw, KAPOOR, Neena, MOLINA, Arturo, AL-KADHIMI, Zaid, FRANKEL, Paul

Volltext

Impact of genomic assays on treatment and outcomes in locally advanced breast cancer von Picado, Omar, Kwon, Deukwoo, Rojas, Kristin, Crystal, Jessica, Wang, Lora, Mahtani, Reshma, Valdes, Frances, Goel, Neha, Kesmodel, Susan B.

Volltext

Interim update of the ATRC-101 phase 1b trial in advanced solid tumors von Chmielowski, Bartosz, Weroha, Saravut John, Ulahannan, Susanna Varkey, Doroshow, Deborah Blythe, Valdes, Frances, Bekaii-Saab, Tanios S., Powderly, John D., Recio-Boiles, Alejandro, Berlin, Jordan, Xing, Yan, Khurana, Sudha, Bishop, Philippe, Isakoff, Steven J., Weinberg, Benjamin Adam

Volltext

Abstract P2-13-45: Interim results of a phase 1 study of the novel immunotoxin MT-5111 in patients with HER2+tumors von Van Tine, Brian A., Mita, Monica, Barve, Minal A., Hamilton, Erika P., Brenner, Andrew J., Valdes, Frances, Ahn, Daniel, Hubbard, Joleen, Starr, Jason, Georgy, Angela, Pelham, Joshua, Anand, Banmeet S., Strack, Thomas, Sandri, Andrés Machado, Wainberg, Zev A.

Volltext

Abstract PS5-28: Multiomic advanced diagnostics for CDK 4/6 drug target activation mapping of HR+/HER2- metastatic breast cancer von Abu-Khalaf, Maysa M, Hatzis, Christos, Hodge, K. Alex, Valdes, Frances, Sikov, William, Mita, Monica, Denduluri, Neelima, Awerkamp, Kris, Murphy, Rita, Zelterman, Daniel, Dunetz, Bryant, Petricoin, Emanuel, Pierobon, Mariaelena

Volltext

A phase I open-label study to investigate safety and tolerability, efficacy, pharmacokinetics, pharmacodynamics, and immunogenicity of MT-5111 in patients with HER2-positive tumors von Wainberg, Zev A., Mita, Monica M., Barve, Minal A., Hamilton, Erika P., Brenner, Andrew J., Valdes, Frances, Ahn, Daniel H., Hubbard, Joleen M., Starr, Jason S., Burnett, Christine, Pelham, Joshua, Strack, Thomas, Machado, Andres, Van Tine, Brian A.

Volltext

A phase 1 study of the novel immunotoxin MT-5111 in patients with HER2+ tumors: Interim results von Van Tine, Brian Andrew, Hubbard, Joleen M., Mita, Monica M., Barve, Minal A., Hamilton, Erika P., Brenner, Andrew J., Valdes, Frances, Ahn, Daniel H., Starr, Jason S., Pelham, Joshua, Strack, Thomas, Yuet, Amy, Yurewicz, Diana, Smith, Taunya J., Machado, Andres, Edenfield, William Jeffery, Morikawa, Aki, Okera, Meena, Abdulla, Nihal E., Wainberg, Zev A.

Volltext

A phase 1 study of the novel immunotoxin MT-5111 in patients with HER2+tumors: Interim results von Hubbard, Joleen M., Van Tine, Brian Andrew, Mita, Monica M., Barve, Minal A., Hamilton, Erika P., Brenner, Andrew J., Valdes, Frances, Ahn, Daniel H., Starr, Jason S., Lerner, Susan, Pelham, Joshua, Anand, Banmeet S., Strack, Thomas, Machado Sandri, Andres, Wainberg, Zev A.

Volltext

CDK 4/6 drug target activation mapping of HR+/HER2- metastatic breast cancer for treatment selection and response prediction von Abu-Khalaf, Maysa M., Hatzis, Christos, Hodge, K. Alex, Valdes, Frances, Sikov, William M., Mita, Monica M., Denduluri, Neelima, Awerkamp, Kris, Murphy, Rita, Zelterman, Daniel, Dunetz, Bryant, Petricoin, Emanuel, Pierobon, Mariaelena

Volltext

A phase I study of the novel immunotoxin, MT-5111, in subjects (subj) with HER-2 positive tumors: Interim results von Wainberg, Zev A., Barve, Minal A., Hamilton, Erika Paige, Brenner, Andrew Jacob, Valdes, Frances, Mita, Monica M., González, Valeria, Anand, Banmeet S., Burnett, Christine, Pelham, Joshua, Waltzman, Roger J., Strack, Thomas, Van Tine, Brian A.

Volltext

Abstract CT130: Phase 1 study of the novel immunotoxin MT-5111 in patients with HER-2+tumors von Wainberg, Zev A., Mita, Monica M., Barve, Minal A., Hamilton, Erika P., Brenner, Andrew J., Valdes, Frances, Ahn, Daniel, Hubbard, Joleen, Starr, Jason, Burnett, Christine, Pelham, Joshua, Williams, Eric T., Anand, Banmeet S., Strack, Thomas, Sandri, Andrés Machado, Van Tine, Brian A.

Volltext

Management of adverse events in patients with HER2+ metastatic breast cancer treated with tucatinib, trastuzumab, and capecitabine (HER2CLIMB) von Okines, Alicia Frances Clare, Paplomata, Elisavet, Wahl, Tanya A., Wright, Gail Lynn Shaw, Sutherland, Stephanie, Jakobsen, Erik, Valdes, Frances, Chan, Arlene, Clark, Amy Sanders, Conlin, Alison Katherine, Lustberg, Maryam B., Specht, Jennifer M., Pluard, Timothy J., Zhu, Xiaofu, Krop, Ian E., Gelmon, Karen A., Slamon, Dennis J., Ramos, Jorge, An, Grace, Hamilton, Erika Paige

Volltext

Abstract P2-07-05: Activation of the AKT/mTOR signaling pathway is associated with response to the combination of endocrine therapy and CDK4/6 inhibitor in HR+/HER2- metastatic bre... von Abu-Khalaf, Maysa, Hatzis, Christos, Hodge, K. Alex, Baldelli, Elisa, Sikov, William, Mita, Monica, Valdes-Albini, Frances, Dunetz, Bryant, Petricoin, Emanuel, Pierobon, Mariaelena

Volltext

Phase I study of nelfinavir in liposarcoma von Pan, Janet, Mott, Michelle, Xi, Bixin, Hepner, Ernestine, Guan, Min, Fousek, Kristen, Magnusson, Rachel, Tinsley, Raechelle, Valdes, Frances, Frankel, Paul, Synold, Timothy, Chow, Warren A.

Volltext

Abstract PD3-07: Trastuzumab deruxtecan (T-DXd; DS-8201) with nivolumab in patients with HER2-expressing, advanced breast cancer: A 2-part, phase 1b, multicenter, open-label study von Hamilton, Erika, Shapiro, Charles L, Petrylak, Daniel, Boni, Valentina, Martin, Miguel, Conte, Gianluca Del, Cortes, Javier, Agarwal, Laila, Arkenau, Hendrik-Tobias, Tan, Antoinette R., Debruyne, Philip, Minchom, Anna, Rutten, Annemie, Valdes-Albini, Frances, Yu, Evan Y, Augustine, Bincy, D'Amelio, Anthony, Barrios, Daniel, Hurvitz, Sara A.

Volltext

Phase I trials of PS-341 (bortezomib, B) in combination with topotecan (T) in advanced solid tumors: A potential pharmacokinetic (PK) interaction von Morgan, Robert, Valdes, Frances, Synold, Timothy W., Frankel, Paul Henry, Ruel, Christopher, Carroll, Mary I., Lim, Dean, Cristea, Mihaela C., Koczywas, Marianna, Leong, Lucille A., Chung, Vincent M., Reckamp, Karen L., Shibata, Stephen, Portnow, Jana, Chow, Warren Allen, Twardowski, Przemyslaw, Luu, Thehang H., Somlo, George

Volltext

Abstract OT2-11-01: A phase 1 study of the novel immunotoxin MT-5111 in patients with HER2+ tumors: interim results von Okera, Meena, Van Tine, Brian A., Hubbard, Joleen M., Barve, Minal, Hamilton, Erika, Mita, Monica M., Valdes-Albini, Frances, Ahn, Daniel, Mamuye, Admasu, Pelham, Joshua, Yuet, Amy, Yurewicz, Diana, Liu, Yanning, Sandri, Andres Machado, Edenfield, William J., Morikawa, Aki, Gradishar, William, Kumar, Rajiv, Wainberg, Zev A.

Volltext

Nelfinavir induces liposarcoma apoptosis and cell cycle arrest by upregulating sterol regulatory element binding protein-1 von Chow, Warren A, Guo, Song, Valdes-Albini, Frances

Volltext